SCHEMBL5847384

SCHEMBL5847384

C=C(CC)c1c(CC)nn2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 2/20 0.41
ALDH1A1 P00352 5/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
PDE5A O76074 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
PDE4A P27815 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
CYP2C19 P33261 1/20 0.40
BLM P54132 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
PDE3B Q13370 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683926 0.82 MIF (0.50) MIFALDH1A1MEN1KMT2ANPSR1
SCHEMBL2035471 0.80 EGFR (0.48) MIFALDH1A1MEN1KMT2ANPSR1
SCHEMBL5847756 0.80 MIF (0.48) MIFALDH1A1MEN1KMT2ANPSR1
SCHEMBL12975583 0.79 PDE4B (0.62) MIFALDH1A1MEN1KMT2ANPSR1
SCHEMBL5847842 0.79 MIF (0.41) MIFALDH1A1MEN1KMT2ANPSR1
SCHEMBL5847833 0.79 MIF (0.41) MIFALDH1A1MEN1KMT2ANPSR1
SCHEMBL5847839 0.79 MIF (0.41) MIFALDH1A1MEN1KMT2ANPSR1
SCHEMBL38666633 0.77 EGFR (0.48) MIFALDH1A1MEN1KMT2ANPSR1
SCHEMBL6489300 0.76 DRD4 (0.38) MIFALDH1A1MEN1KMT2ANPSR1
SCHEMBL1780786 0.75 EGFR (0.53) MIFALDH1A1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151109-B2 Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY LLC (US) 2006-12-19 US disclosed
EP-1485384-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS Pharmacia & Upjohn Company LLC (US) 2004-12-15 EP disclosed
EP-1451164-A2 AMIDE DERIVATIVES HAVING IMPROVED SOLUBILITY PHARMACIA & UPJOHN COMPANY (US) 2004-09-01 EP disclosed
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators PHARMACIA & UPJOHN COMPANY 2004-01-01 US disclosed
WO-2003078435-A1 PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS PHARMACIA & UPJOHN COMPANY LLC (US) 2003-09-25 WO disclosed
WO-2003006440-A2 AMIDE-CONTAINING COMPOUND HAVING IMPROVED SOLUBILITY AND METHOD OF IMPROVING THE SOLUBILITY OF AN AMIDE-CONTAINING COMPOUND PHARMACIA & UPJOHN COMPANY (US) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002511-A1 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators CRHR1, HTR5A, CRH MIF 1152/4885ALDH1A1 911/4885MEN1 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.